

ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018

Lyon (France) and Cambridge, Mass. (U.S.), November 5, 2018 – ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a Key Opinion Leader (KOL) breakfast symposium, focused on the potential of eryaspase to treat patients with pancreatic cancer and triple-negative breast cancer, on Wednesday, November 7, 2018 from 8:00 A.M. – 11:00 A.M. ET in New York City.

The event will feature four guest speakers, who will highlight the treatment landscape and unmet medical need in pancreatic and triple negative breast cancers, and zoom in on the evolving field of cancer metabolism:

- Prof. Dr. Ahmed Awada, Head of the Oncology Medicine Department at the Jules Bordet Institute, Brussels, Belgium
- Prof. Dr. Javier Cortes, Head of the Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain
- Prof. Dr. Pascal Hammel, Head of the Digestive Oncology unit at Beaujon Hospital, Paris VII University, Paris, France
- Prof. Dr. Manuel Hidalgo Medina, Chief of Hematology/Oncology Division at Beth Israel Deaconess Medical Center, Boston, MA, United States

Members of ERYTECH management will provide an overview of the company's technology and clinical pipeline.

Webcast Information

A live audio webcast of the KOL breakfast and replay will be available online from the Investors section of ERYTECH's website at www.erytech.com. A replay of the presentation will be accessible on the ERYTECH website for 30 days following the presentation.

About ERYTECH and eryaspase: www.erytech.com

ERYTECH is a clinical-stage biopharma company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

ERYTECH's prime focus is on the development of products that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company's lead product candidate, eryaspase, L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell's altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH's next product candidate erymethionase, methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is being prepared to enter Phase 1 clinical development .

ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).

ERYTECH produces product candidates at its GMP-approved and operational manufacturing site in Lyon, France, and the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FRO011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS

ERYTECH
Eric Soyer
CFO/COO

+33 4 78 74 44 38
investors@erytech.com

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 1 44 71 98 52
erytech@newcap.eu



Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH’s clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the FDA and EMA regarding ERYTECH’s product candidates. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2017 Document de Référence filed with the AMF in April 2018 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 24, 2018 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.